Results 1 to 10 of about 36,968 (260)
Journal of Pharmacy and Bioallied Sciences, 2012 Bisphosphonates are used widely for variety of bone condition, most notably IV bisphosphonates in the treatment of metastic bone lesion and oral bisphosphonates for osteoporosis.
Nalliappan Ganapathy +4 more
doaj +3 more sources
Endocrinology and Metabolism Clinics of North America, 2003 Osteoporosis is the result of bone loss due to an imbalance in bone turnover such that bone resorption exceeds bone formation. Bisphosphonates are potent inhibitors of osteoclast activity that reduce bone turnover and re-establish the balance between bone resorption and formation. In clinical studies, several bisphosphonates prevent bone loss, preserve
Julie T, Lin, Joseph M, Lane
openaire +7 more sources
Bisphosphonates for Osteoporosis [PDF]
New England Journal of Medicine, 2011 Bisphosphonates are compounds characterized by a P-C-P structure. They act essentially on bone, inhibiting bone resorption. Through this mechanism they decrease bone loss, increase bone mineral density, and decrease bone turnover. They are therefore administered in diseases with elevated bone destruction, such as Paget's disease, metastatic bone ...
Vis, M., Dijkmans, B.A.C., Lems, W.F.
+9 more sources
Frontiers in Chemistry, 2022 Phosphonates and bisphosphonates are stable analogs of phosphates and pyrophosphates that are characterized by one and two carbon–phosphorus bonds, respectively.
Babak Kaboudin +3 more
doaj +1 more source
Journal of Orthopaedic Translation, 2020 Objective: The objective of this study was to assess the efficacy and safety of denosumab therapy in osteoporotic postmenopausal women who were previously treated with bisphosphonates. Methods: Meta-analyses of four available randomised controlled trials
Yilin Zhu +9 more
doaj +1 more source
Therapeutic Advances in Chronic Disease, 2022 Background: Bisphosphonates are a type of medication that prevents the loss of bone density. Secondary childhood osteoporosis reduces bone strength and results in an increased risk of fragility fracture.
Huawei Zhao +5 more
doaj +1 more source
Atypical femur fractures associated with chronic bisphosphonates use: A case series with 66 patients [PDF]
Revista Brasileira de Ortopedia, 2022 Objective The present study aims to describe outcomes from a series of surgically treated patients with atypical femoral fracture due to bisphosphonates use, in addition to correlate the time of previous medication use with fracture consolidation time ...
Guilherme Guadagnini Falotico +5 more
doaj +1 more source
Annals of the New York Academy of Sciences, 2006 Abstract: Bisphosphonates belong to a class of compounds similar to pyrophosphate. In these compounds the oxygen atom of the pyrophosphate is replaced by a carbon atom resulting in a P‐C‐P bond. They exert a potent inhibitory effect on osteoclasts and are therefore potent antiresorptive agents. They reduce bone turnover, increase bone mineral density,
Lambrinoudaki, I. +2 more
openaire +4 more sources
Bisphosphonate nephrotoxicity [PDF]
Kidney International, 2008 Bisphosphonates are valuable agents for the treatment of post-menopausal osteoporosis (PMO), hypercalcemia of malignancy, and osteolytic bone metastases. Oral bisphosphonates are used mainly to treat PMO and are not associated with significant nephrotoxicity.
Perazella, Mark A., Markowitz, Glen S.
openaire +2 more sources
eJournal of Oral Maxillofacial Research, 2023 Objectives: The aim of this cross-sectional study is to evaluate Lithuanian fourth- and fifth-year dental students' knowledge about bisphosphonates and bisphosphonate-related osteonecrosis of the jaw. Material and Methods: The anonymous survey using a
Greta Sereikaite +4 more
doaj +1 more source